This document contains 7 multiple choice questions about anticoagulant drugs. The questions cover topics like: the time needed for an aPTT to reflect steady-state heparin levels after bolus/infusion initiation; direct-acting plasminogen activators; drugs that inhibit cyclooxygenase enzymes; the mechanism of action and factors affected by warfarin; drugs that interact with warfarin; the mechanism of action of mini-dose heparin; and a correct statement about fibrinolytic agents.
This document contains 7 multiple choice questions about anticoagulant drugs. The questions cover topics like: the time needed for an aPTT to reflect steady-state heparin levels after bolus/infusion initiation; direct-acting plasminogen activators; drugs that inhibit cyclooxygenase enzymes; the mechanism of action and factors affected by warfarin; drugs that interact with warfarin; the mechanism of action of mini-dose heparin; and a correct statement about fibrinolytic agents.
This document contains 7 multiple choice questions about anticoagulant drugs. The questions cover topics like: the time needed for an aPTT to reflect steady-state heparin levels after bolus/infusion initiation; direct-acting plasminogen activators; drugs that inhibit cyclooxygenase enzymes; the mechanism of action and factors affected by warfarin; drugs that interact with warfarin; the mechanism of action of mini-dose heparin; and a correct statement about fibrinolytic agents.
1. A patient diagnosed with a deep venous thrombosis is begun
on a heparin infusion of 1000 U/HR after a 5000 U Bolus. The earliest you can draw blood for an aPTT reflecting steady-state heparin is: 1. 4 hours 2. 7.5 hours 3. 12 hours 4. 24 hours 5. None of the above
4. Correct statements about the action of warfarin include: A. warfarin is structurally similar to vitamin K and competitively inhibits liver synthesis of clotting factors B. warfarin inhibits vitamin K epoxide reductase C. the onset of warfarin action may be prolonged due to the long half-life of factor VII D. factors II, VII, IX, and X are not activated (carboxylated) when warfarin is administered in therapeutic doses 1. A,B,C 2. A,C 3. B,D 4. D only 5. All of the above
5. Drugs which interact with warfarin to increase its anticoagulant effect include: A. ranitidine B. trimethoprim/sulfamethoxazole C. rifampin D. nonsteroidal anti-inflammatory drugs 1. A,B,C 2. A,C 3. B,D 4. D only 5. All of the above
6. The mechanism of action of mini-dose heparin is correctly described by: A. factor X is more sensitive to heparin than are other serine protease factors B. mini-dose heparin is useful prophylactically rather than during active clot formation C. by inhibiting factor X activation, a relative block of the clotting cascade develops, with less thrombin formed D. the major action is to directly inhibit factor II, which is very sensitive to heparin 1. A,B,C 2. A,C 3. B,D 4. D only 5. All of the above
7. The correct statement about fibrinolytic agents is: 1. streptokinase acts directly to activate plasminogen 2. urokinase acts directly to activate plasminogen 3. tissue-type specific plasminogen activator is more fibrin specific than streptokinase 4. side effects of t-PA include skin rash, allergic reactions, and development of antibodies 5. have been shown to increase mortality when given in the setting of an acute myocardial infarction